Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results and what they mean for your portfolio. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're breaking down Prologis' Q1 2026 earnings - and wow, what a quarter for the industrial real estate giant.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's talk about these numbers because Prologis just delivered some seriously impressive results.

**ALEX:** They really did, Jordan. Let me start with the headline numbers. Core FFO came in at $1.50 per share including net promote expense, and $1.52 excluding it - both beating expectations. But what really caught my eye was that record leasing number: 64 million square feet of signings in just one quarter.

**JORDAN:** That's massive. And here's what I find fascinating - their leasing pipeline didn't just maintain after this record quarter, it actually reached new highs. That tells me the underlying demand is incredibly robust. Plus, occupancy hit 95.3%, which exceeded their own expectations.

**ALEX:** The retention rate was impressive too - nearly 76%. But Jordan, let's talk about what's really driving this story: their expansion beyond traditional logistics into data centers. They started $2.1 billion of new development this quarter, with $1.3 billion of that going to data center projects.

**JORDAN:** This is where it gets really interesting from an investment perspective. CEO Dan Letter mentioned they have 1.3 gigawatts under letter of intent and all of their power pipeline sites are in active discussions. Tim Arndt, their CFO, said they ended the quarter with 5.6 gigawatts of energy either secured or in advanced stages.

**ALEX:** And here's the kicker - Arndt said that just assuming a basic power shell format at $3 million per megawatt, their current pipeline could provide well over $15 billion of investment opportunity. That's not even counting the turnkey format which would be multiples of that.

**JORDAN:** The data center story is compelling, but let's not forget their bread and butter logistics business is still performing. U.S. logistics markets absorbed 45 million square feet on a seasonally adjusted basis - that was actually ahead of their forecast. And vacancy rates stayed stable at 7.5%.

**ALEX:** What I found encouraging was the rent growth story. Market rents grew 30 basis points globally - and this was the first increase in 2.5 years. That suggests we might be at an inflection point where the supply-demand dynamics are finally shifting in landlords' favor.

**JORDAN:** Exactly. And their lease mark-to-market of 17% on a net effective basis represents about $750 million of embedded NOI at current spot rents. That's a lot of upside still to capture as occupancies improve.

**ALEX:** Now, let's address the elephant in the room - the geopolitical backdrop. Letter specifically mentioned the Middle East conflict and its potential impact on their business. How did management handle this?

**JORDAN:** I thought Letter was refreshingly direct about it. He acknowledged the uncertainty, especially around energy prices and inflation pressures, but he focused on what they're actually seeing in their data. He said seven weeks into the conflict, most customers are telling them their 2026 business plans remain unchanged.

**ALEX:** That's a key point. He contrasted this with April 2025 when tariff-related uncertainty caused an immediate pause in leasing activity. This time, he's not seeing that same pattern - March was actually a very active month for new leasing.

**JORDAN:** Speaking of capit

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with Jordan to dive into Prologis' Q4 2025 earnings call. Before we get started, I want to remind everyone that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Thanks Alex. And wow, what a quarter for Prologis! They really delivered some impressive numbers. Let's start with the headline metrics - they hit core FFO of $1.44 per share, landing at the top end of their guidance range. But what really caught my eye was their occupancy performance.

ALEX: Absolutely! They finished the year with 95.8% occupancy, which is remarkable when you consider the broader industrial real estate market has been struggling. Tim Arndt mentioned they're outperforming the broader U.S. market by 300 basis points. That's a massive gap that really shows the quality of their portfolio.

JORDAN: And let's talk about that leasing momentum - 57 million square feet of leases signed in just the fourth quarter alone. But here's what's really interesting: they're seeing net effective rent changes of 44% for the quarter, contributing about $60 million in annualized NOI. Even more exciting, they still have an 18% lease mark-to-market representing nearly $800 million of embedded NOI growth.

ALEX: That embedded growth is huge for investors to understand. It means Prologis can grow NOI without market rents even improving further. Speaking of market conditions, I found Chris Caton's commentary particularly insightful. He mentioned they're seeing three stages of market inflection - evidence of enduring demand, building occupancy, and then rent inflection. They're now seeing all three at various stages across their markets.

JORDAN: Right, and the demand drivers are really compelling. E-commerce represented about 20% of their new leasing activity over the past year, making 2025 the best year for e-commerce leasing since 2021. That threefold space multiplier for e-commerce versus traditional retail continues to be a powerful tailwind.

ALEX: Now let's shift to what might be the most exciting part of this story - their data center expansion. Tim mentioned they've expanded their power access to 5.7 gigawatts, and here's the kicker: they have 1.2 gigawatts currently in LOI or pending lease execution. That's massive scale.

JORDAN: The numbers are staggering when you think about it. Just a year ago, they talked about potentially reaching 10 gigawatts of power over ten years. Now they're already at nearly 6 gigawatts after just one year. Dan Letter was careful to clarify that the 10 gigawatt figure represents the total opportunity universe, but the pace of progress is clearly accelerating.

ALEX: And what's smart about their approach is the discipline. Tim explained they're thinking about roughly 60-70% of projects being "powered shell" format versus full turnkey. The powered shell approach is less capital intensive but still captures significant value. In their 2026 guidance, they expect data centers to represent about 40% of their $4-5 billion development start forecast.

JORDAN: Let's talk about that guidance because it's quite robust. They're forecasting development starts between $4-5 billion on an owned and managed basis. Same-store NOI growth is expected to be 4.25% to 5.25% on a net effective basis. And core FFO is guided to $6.00-$6.20 per share including promote expenses.

ALEX: One thing that stood out from the Q&A was the international strength. Japan delivered occupancy above 97% with nearly 600 basis points of outperformance versus their local market. Europe posted its first quarter of positive rental growth in two years. This global diversification is really paying dividends.

JORDAN: And we can't forget

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Procter & Gamble's fiscal Q4 and full-year 2026 results — and there's a lot to unpack, from a CEO transition on the board to a fresh look at fiscal 2027 guidance.

But before we get into it, quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Alright, so let's start with the news that isn't really about the numbers — Jon Moeller is retiring from the board after 38 years at P&G. He's held basically every top job there: CFO, COO, CEO, Executive Chairman. That's a long goodbye for someone who shaped the company's current structure.

ALEX: Right, and CEO Shailesh Jejurikar spent real time on the call thanking him before handing it to CFO Andre Schulten for the actual numbers. So let's get into those. For the full fiscal year, organic sales grew just over 1%, core EPS came in at $6.89, up about 1%. Not a blowout year, but they hit their guidance ranges despite what they called a "very volatile environment."

JORDAN: And that volatility really showed up in the fourth quarter specifically. Core EPS was $1.43, down 3% year-over-year — on a currency-neutral basis, down 5%. They pointed to a spike in energy, transportation, and material costs, about six cents a share, that was mostly offset by tariff refunds.

ALEX: There was also this interesting wrinkle in the U.S. business — a gap between what's called "sell out" versus "sell in." Basically, consumer purchases at retail — sell out — were up 2%, but P&G's shipments to retailers — sell in — were down 1%. That's a three-point gap.

JORDAN: Yeah, and management explained that pretty clearly — Amazon Prime Day shifted into late June this year instead of early July, which changed how promotional spending got recognized, plus retailers were drawing down inventory. It's a timing issue more than a demand issue, and honestly analysts pushed hard on this exact point during Q&A.

ALEX: They did. One analyst basically asked, "Is this a P&G-specific problem?" And Schulten's answer was pretty blunt — he said it's simply because P&G is bigger and has higher velocity than competitors, so when retailers want to cut inventory fast, they trim the biggest, fastest-moving brand on the shelf. It's math, not strategy failure.

JORDAN: What stood out to me geographically was China. Organic sales there grew 4% for both the quarter and the year, and P&G said they're growing share in China for the first time in 15 quarters. Baby care was the star — they highlighted this premium diaper using silk materials that's delivered double-digit growth for six straight quarters and now has them back as the number one baby care brand in the country.

ALEX: That silk diaper story is a nice example of their broader playbook — figure out what consumers actually want, translate it into product innovation, and let that drive both category growth and share. They gave a bunch of these: Vicks cough and cold in Latin America, Pantene in Germany leaning into influencer marketing, SK-II shifting to lifestyle content on social commerce.

JORDAN: The Tide story was probably my favorite, though. They did the biggest upgrade to original Tide liquid in over two decades — same price, much better performance — and it went from declining sales to high single-digit growth. Jejurikar said flat out it beat their own expectations.

ALEX: And that's really the "stronger core" half of their strategy — fix what you already have. The other half is "bigger more," which is Tide Evo, this new unit-dose detergent with no plastic packaging, built on over 50 patents. National rollout is h

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into Procter & Gamble's Q2 2026 earnings call. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And what a quarter to unpack! P&G just reported what management called their "softest quarter of the fiscal year," but there's actually a lot more optimism here than that headline might suggest.

**ALEX**: Absolutely. Let's start with the numbers, Jordan. Organic sales were flat year-over-year, which sounds underwhelming until you understand the context. They had some major base period disruptions - remember those port strikes and hurricanes last October that caused all that inventory loading?

**JORDAN**: Right, and CFO Andre Schulten was very clear about this. The biggest impacts hit baby care, feminine care, and family care - all concentrated in the U.S. market. But here's the interesting part: the rest of P&G's business outside the U.S. actually grew nearly 3%. That's a pretty solid foundation.

**ALEX**: That's a great point. When you look at the regional breakdown, you see some real bright spots. Latin America grew 8%, Greater China was up 3% - which is impressive given the challenging consumer environment there. Europe's enterprise markets grew 6%. It really was a U.S.-centric slowdown.

**JORDAN**: And speaking of China, I loved CEO Shailesh Jejurikar's example about their Pampers Prestige innovation. They tapped into this deep cultural insight about Chinese parents wanting the best for their babies, and literally incorporated silk - this symbol of luxury for over 2,000 years - into their diapers. It's driving double-digit growth and they've gained nearly three points of market share.

**ALEX**: That's exactly the kind of consumer-centric innovation P&G is doubling down on. Jejurikar talked extensively about what he called "the next important phase of constructive disruption." They're not just tweaking around the edges - they're fundamentally reimagining how a CPG company operates in today's fragmented media landscape.

**JORDAN**: The technology transformation really stood out to me. They've built this massive data lake with petabytes of consumer information, AI-powered tools for product development, and supply chain systems that can react autonomously to demand signals. But Jejurikar was realistic about the timeline - he said it'll take 12 to 18 months to get this "future evenly distributed" across the company.

**ALEX**: Let's talk margins for a second. Core EPS came in at $1.88, flat with last year. But they delivered 270 basis points of productivity improvements, which they reinvested back into innovation and marketing. That's classic P&G - they're not letting a tough quarter derail their long-term investment strategy.

**JORDAN**: And they're maintaining all their full-year guidance, which shows real confidence. Organic sales growth of flat to plus 4%, core EPS growth of flat to plus 4%. They're basically saying "trust us, the back half is going to be much stronger."

**ALEX**: The Q&A session revealed some interesting dynamics too. When analysts pressed about U.S. market share losses, Schulten was pretty direct - they have work to do to recover share, but they're already seeing progress in categories like family care and laundry where they've made those innovation interventions.

**JORDAN**: I thought the discussion about e-commerce was fascinating. One analyst pointed out that Amazon is driving 60-80% of growth in P&G's categories. Jej

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Pfizer's second quarter 2026 results, and there's a lot to unpack — from a CFO transition to some really important pipeline news. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: And there's plenty to research here, Alex. Let's start with the headline news that isn't even about the numbers — Pfizer's CFO Dave Denton is departing, and Cecile Guegan is stepping in as interim CFO. She's not new to the building though — she's been deeply involved in the Seagen, Metsera, and Biohaven deals and Pfizer's capital allocation strategy.

ALEX: Right, so this feels like a continuity move rather than a shake-up. Now let's get to the numbers. Q2 revenue came in at $15 billion, up just 1% operationally year-over-year — but here's the key detail: strip out COVID products, and the underlying business actually grew 5% operationally.

JORDAN: That's the story of this whole quarter — COVID is a drag, everything else is humming. Adjusted diluted EPS was $0.77, beating expectations. And get this — Pfizer has now beaten EPS expectations for ten straight quarters, and revenue expectations in nine of the last ten. That's a pretty remarkable execution streak.

ALEX: They also raised full-year revenue guidance to a range of $60.5 to $62.5 billion, up $500 million at the midpoint, even while cutting their COVID revenue forecast from $5 billion to $4 billion.

JORDAN: Which tells you how strong the non-COVID business is performing to more than offset that. EPS guidance was reaffirmed at $2.80 to $3, though that now absorbs a $0.10 hit from the Innovent Biologics deal that closed in Q3.

ALEX: Let's talk about those big acquisitions, because this is really the crux of Pfizer's growth story. The Seagen, Metsera, and Biohaven deals — revenue from acquired products grew 25% operationally. PADCEV, the bladder cancer drug from Seagen, just got FDA approval expanded to muscle-invasive bladder cancer regardless of cisplatin eligibility, and it grew over 20% this quarter.

JORDAN: And on the Metsera side, that's the obesity bet — nirubenatide, their monthly GLP-1 candidate. They're targeting a $150 billion obesity market and aiming for first approval in 2028. They shared data suggesting it could be competitive with — maybe even better than — some existing weekly therapies like Wegovy, though as always, cross-trial comparisons come with caveats.

ALEX: Biohaven's NURTEC is also doing well, still leading the oral CGRP migraine class, with new trials underway for chronic and menstrual migraine.

JORDAN: Now, it wasn't all good news. There was a real setback in oncology — the phase III trial for sigvotatug vedotin, or SV, missed its primary overall survival endpoint in second-line-plus non-small cell lung cancer. That contributed to a $4.3 billion non-cash impairment charge, which is why Pfizer actually posted a GAAP loss per share of $0.04 this quarter.

ALEX: But management pushed back on writing off SV entirely — they highlighted a subgroup of patients on just one prior therapy that showed a 2.5-month survival benefit, and they're leaning into earlier-line lung cancer combos with pembrolizumab, where phase I data showed an 82% response rate.

JORDAN: There's also encouraging news on mevrometostat, their prostate cancer drug being developed alongside XTANDI. Phase I data showed it roughly doubled progression-free survival, and the market really zeroed in on this during Q&A — analysts are watching the MEV-Pro1 readout expected in Q4.

ALEX: Speaking of Q&A, one exchange I found telling was about the dividend. An analyst

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
# Beta Finch Podcast Script: Pfizer Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the latest corporate results. I'm Alex, and joining me as always is Jordan. Today we're unpacking Pfizer's Q1 2026 earnings call, and folks, there's quite a bit to unpack here.

Before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Pfizer! They really came out swinging with some impressive numbers and some game-changing legal developments. Should we start with the headline figures?

**ALEX:** Absolutely. Pfizer reported Q1 revenues of $14.5 billion, which actually exceeded their own expectations. That's a 2% operational increase overall, but here's the kicker - if you strip out their COVID products, the underlying business grew about 7% operationally. That's solid growth in a challenging environment.

**JORDAN:** And the earnings story is even better. They hit $0.75 in adjusted diluted earnings per share, again beating expectations. What really caught my attention though was their launched and acquired products - these grew 22% operationally to $3.1 billion in the quarter. That's the portfolio transformation strategy Albert Bourla has been talking about really starting to pay off.

**ALEX:** Speaking of transformative developments, we need to talk about the elephant in the room - or should I say, the legal victories in the room. Pfizer had two major legal wins that could reshape their entire growth trajectory post-2028.

**JORDAN:** Right, the Vyndamax patent settlement is huge. This drug, which treats a rare heart condition, was facing generic competition, but now Pfizer has extended exclusivity until mid-2031. We're talking about a $6 billion-plus product here, Alex. CEO Albert Bourla said this "has the potential to change the growth profile of the company significantly post-2028."

**ALEX:** And then there's the Belgian court ruling on their Comirnaty contracts with EU countries. CFO Dave Denton called this "a positive for future EPS and cash flow." These aren't just minor legal technicalities - these are major financial game-changers that give Pfizer much clearer visibility into their cash flows.

**JORDAN:** Which brings us to one of the most interesting parts of the call - Pfizer's new confidence about their post-2028 growth trajectory. Bourla said they now expect a "5-year period of high single-digit revenue CAGR" starting in 2029. That's a pretty bold statement, especially when you consider they're still navigating some significant patent cliff challenges.

**ALEX:** Let's break that down for listeners. CAGR stands for Compound Annual Growth Rate. So Pfizer is essentially saying that starting in 2029, they expect to grow revenues at a high single-digit percentage rate - so probably 7-9% annually - for five straight years. That would be impressive for any pharma company, let alone one coming off the COVID revenue peaks.

**JORDAN:** And the foundation for that confidence seems to be their pipeline and their recent acquisitions. They mentioned having about 20 pivotal study starts planned this year, 8 key data readouts, and 4 regulatory decisions. That's a packed R&D calendar. They're particularly excited about their oncology portfolio, especially after the Seagen acquisition.

**ALEX:** The oncology story is fascinating. They reported 20% year-over-year growth in their Seagen products, and they've got some potentially blockbuster readouts coming. There's Padcev for bladder cancer, which affects over 600,000 patients globally, and their multiple myeloma drug Elrexfio just hit

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from the latest quarterly reports. I'm Alex.

**JORDAN**: And I'm Jordan. Before we dive in, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks Jordan. Today we're breaking down Pfizer's Q4 2025 earnings, and wow - this was a packed call. We've got solid financial performance, major obesity drug developments, and some really interesting strategic moves. Let's start with the numbers, Jordan.

**JORDAN**: The headline numbers tell a story of resilience, Alex. Pfizer posted $62.6 billion in full-year revenue versus $63.6 billion last year - that's a 2% operational decline. But here's the key detail: when you strip out their COVID products, they actually grew operational revenue by 6%.

**ALEX**: That's huge because it shows the underlying business is healthy. What about profitability?

**JORDAN**: Even better news there. Adjusted earnings per share came in at $3.22 versus $3.11 last year, beating expectations. They expanded gross margins to 76%, and their recently launched and acquired products - which is really their growth engine - delivered over $10 billion in revenue with 14% operational growth.

**ALEX**: Now, the elephant in the room with Pfizer has always been their COVID business decline. How bad was that impact in Q4?

**JORDAN**: Pretty significant. COVID products dropped about 40% operationally year-over-year in Q4. But Alex, this is actually old news at this point. What's more interesting is how well they're managing through it. Their non-COVID business grew 9% in the quarter, driven by products like Abrysvo, Eliquis, Prevnar, and the Vyndaqel family.

**ALEX**: Speaking of managing through challenges, they reaffirmed their 2026 guidance today. Walk us through what they're expecting.

**JORDAN**: They're guiding for $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS for 2026. What's notable is they're expecting COVID revenues to drop to about $5 billion, and they're anticipating $1.5 billion in revenue compression from generic competition. But even with those headwinds, they expect their core business excluding COVID and loss-of-exclusivity products to grow about 4% operationally.

**ALEX**: Now let's talk about the real headline from today's call - their obesity drug data. This feels like a potential game-changer, Jordan.

**JORDAN**: Absolutely, Alex. They announced results from their VESPER-3 study for PF-3944, which is their investigational obesity treatment. And the key differentiator here is that it's designed for monthly dosing instead of weekly like current GLP-1 drugs.

**ALEX**: Monthly dosing - that's a big deal for patient convenience. What kind of weight loss are we talking about?

**JORDAN**: The data showed 10-12% placebo-adjusted weight loss at 28 weeks for their planned phase 3 doses. But here's what's really interesting - their modeling suggests the higher dose they're planning could deliver nearly 16% weight loss. And importantly, they didn't see a weight loss plateau at 28 weeks, suggesting patients could lose even more weight over time.

**ALEX**: How does that stack up against what's already on the market?

**JORDAN**: It's competitive with existing weekly GLP-1s like Ozempic and Wegovy, but the monthly dosing is the real differentiator. During the Q&A, their commercial team emphasized that reducing from four injections per month to just one could be a major advantage for patient compliance and switching existing patients to their therapy.

**A

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
Welcome to Beta Finch, your AI-powered earnings breakdown of the calls that move markets. Today we're digging into PepsiCo's Q2 2026 results.

ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan, and today we're breaking down PepsiCo's second quarter 2026 earnings call. This one's got a real tale-of-two-businesses vibe — strong international, choppier North America. Before we dive in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Right, and there's a lot to unpack here, Alex. This wasn't a blowout quarter, but it also wasn't a disaster — it's more of a "here's exactly where the pressure points are" kind of call.

ALEX: Let's start with the headline numbers. First-half revenue grew almost 7% company-wide, which is solid. Global volumes were up 3% in foods and 2% in beverages — CEO Ramon Laguarta called that the fastest volume growth since 2022.

JORDAN: And on earnings, reported EPS grew 6% in the first half, constant currency EPS up 3%. They reaffirmed full-year guidance, though CFO Steve Schmitt flagged it might land toward the low end of their EPS range.

ALEX: The story underneath those numbers, though, is really about a split business. International is on fire — set to cross $40 billion this year, growing 7% and accelerating. Meanwhile North America, especially the food business, PFNA, came in softer than expected.

JORDAN: Yeah, PFNA volume was flat in the quarter. And that's notable because PepsiCo spent the first half of the year specifically investing in affordability — lowering prices, portion control packs — to get salty snacks volume growing again after a stretch of decline.

ALEX: And it kind of worked, right? Laguarta made the point that the category went from negative volume to positive, and PepsiCo is actually gaining share within that. So directionally the strategy's working, just not as fast as hoped.

JORDAN: Right, and he was pretty candid about why: gas prices. Rising fuel costs hit convenience and gas station channels hard — those impulse-purchase locations where price sensitivity shows up fast. People are pulling into the pump but not converting that traffic into snack and drink purchases the way they used to.

ALEX: That convenience-and-gas weakness actually shows up directly in the numbers too. PBNA — the North America beverage business — saw operating margin down about 90 basis points. Steve Schmitt broke that into three pieces: about half tied to the Alani Nu commercial arrangement, then the soft convenience-and-gas channel, and product mix.

JORDAN: What I found interesting was management resisting the idea of some big "reset" — a phrase one analyst used. Laguarta pushed back pretty firmly, saying they don't need one because of record productivity gains funding the growth investments.

ALEX: There was also a nice tailwind mentioned — tariff refund claims from last year, expected to add about a full point of EPS growth for the full year. That's helping offset rising commodity costs, particularly some inflation expected in Europe and the Middle East in the back half.

JORDAN: On the international side, it's honestly the highlight of the call. Laguarta did a world tour — Vietnam, Thailand, China, the Middle East, all more resilient than expected despite higher gas prices there too. Europe's getting a real boost from World Cup sponsorship activations. Latin America's a bit softer but still trending positive.

ALEX: And Schmitt added that international operating margin actually grew a full point in the quarter — so it's not just top-line growth, it's profitable, efficient growth.

JORDAN: One thing

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that matter. I'm Alex, and I'm here with my co-host Jordan to break down PepsiCo's Q1 2026 earnings call. Jordan, this was quite an interesting quarter with some geopolitical backdrop we don't usually see.

**JORDAN**: Absolutely, Alex. And before we jump into the numbers, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Thanks, Jordan. Now, let's talk PepsiCo. The big headline here is that they're showing sequential improvement across their business units, particularly in North America Foods, which has been a challenge area. They maintained their organic revenue guidance of 2% to 4% for the year, with expectations to hit the higher end in the back half.

**JORDAN**: Right, and what's fascinating is how they're navigating this Iran conflict situation. CFO Steve Schmitt was pretty transparent about it - they have 6 to 12-month hedging programs in place, and surprisingly, they're not seeing major supply chain disruptions. In fact, CEO Ramon Laguarta mentioned they might actually have better supply chain resilience than some competitors, especially in the food business.

**ALEX**: That's a great point about competitive advantage during tough times. Let's break down the segment performance. The North America Foods business, which has been under pressure, showed 2% volume growth in Q1. Jordan, this seems like a real turnaround story.

**JORDAN**: It really is, Alex. What's impressive is the scale of this turnaround - they added 300 million new consumption occasions in Q1 compared to the same period last year. That's massive. Ramon talked about this being a "holistic commercial strategy" involving better value propositions, more shelf space, brand restaging for Lay's and Tostitos, and accelerated innovation in what they call "permissible and functional" products.

**ALEX**: And they're seeing results in market share too, right? They mentioned gaining positive share in both volume and value recently, which had been a key performance indicator they set for themselves.

**JORDAN**: Exactly. The away-from-home business is growing at 3x the company average, and their permissible portfolio brands like SunChips and Smartfood are seeing double-digit growth in some cases. But here's what I found most interesting - their costs for North America Foods actually went *down* in Q1 while they're investing more. That speaks to their productivity initiatives really paying off.

**ALEX**: That productivity story is huge. Let's talk about the beverage side - PBNA grew 9% total, which is pretty impressive.

**JORDAN**: Yeah, but it's a mixed bag when you dig deeper. The headline 9% growth includes about 7 points from new platforms and acquisitions like Poppi and expanded energy drink distribution. The organic growth was around 2%. They're still dealing with a case pack water transition that pressured volumes, but Ramon expects that to turn positive in coming quarters.

**ALEX**: One thing that stood out from the Q&A was the discussion around SNAP benefit restrictions and GLP-1 drugs. These are newer headwinds the industry is watching closely.

**JORDAN**: True, eight states began SNAP restrictions in Q1, mainly affecting beverages and candy. But Steve Schmitt said it's too early to draw conclusions. What's more interesting is how they're positioning for these secular changes - they're doubling down on innovation in functional and permissible products, which could actually benefit from health-conscious trends.

**ALEX**: The interna

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
WELCOME TO BETA FINCH — PANW Q4 FY2026

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, here with Jordan, and today we're digging into Palo Alto Networks' fiscal Q4 2026 results. This one's a big report to close out their fiscal year.

JORDAN: Before we jump in — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Right, so let's get into it, because Palo Alto had a genuinely record quarter. RPO — that's remaining performance obligations, basically the backlog of contracted future revenue — crossed $20 billion for the first time, landing at $21.2 billion, up 34%.

JORDAN: And the number that really jumped out to me was Next-Generation Security ARR, or NGS ARR, hitting $9.1 billion, up 63%. They added almost $1 billion in net new NGS ARR in a single quarter. CFO Dipak Golechha pointed out that's roughly what the entire company's NGS ARR was back in his first quarter as CFO in 2021. That's the kind of comparison that really puts scale into perspective.

ALEX: Total revenue for the quarter was $3.41 billion, up 34%, and full-year revenue came in at $11.5 billion, up 24%. Non-GAAP EPS beat guidance at $1.02, and operating margin for the year expanded to 29.2%.

JORDAN: What's notable is that margin expansion happened while they were digesting their two biggest acquisitions ever — CyberArk, now rebranded Idira, and Chronosphere. Usually big M&A drags on margins for a while, but management said CyberArk's cost synergies are three to six months ahead of schedule.

ALEX: Let's talk strategy, because CEO Nikesh Arora spent a lot of time on what he called three AI "inflection points" over the last several months — the shift from prompting to autonomous agents, the "Mythos moment" where AI models got scary good at finding vulnerabilities, and now a move toward open-weight, sovereign AI models. His overall thesis: all three point toward the same conclusion.

JORDAN: Which is platformization — get customers to consolidate onto one unified security architecture instead of stitching together point products. They hit about 220 net new "platformizations" in the quarter, more than double the pace from two years ago, and platformized customers are showing net revenue retention above 120%.

ALEX: They also called out some serious deal sizes — a $126 million deal with a global telecom, $72 million with an IT services firm, $53 million with a payments company. And Prisma AIRS, their AI security product, crossed $100 million in ARR in just four quarters — fastest product scale in company history.

JORDAN: XSIAM, their security operations platform, is also cruising — over $700 million in ARR, up 70%, past 1,000 customers. And on the observability side, since closing Chronosphere, that ARR has more than doubled past $500 million. Combined, XSIAM and observability are now a billion-dollar-plus business that basically didn't exist a few years ago.

ALEX: There was also a bit of breaking news on the call — they closed an acquisition of a company called Console the same day, focused on AI-driven IT and security operations, folding into their Cortex team.

JORDAN: On the Q&A side, I thought the most candid moment was Nikesh basically saying M&A isn't a strategy for them — it's a consequence of watching 40 or 50 funded startups and jumping in when one of them nails a technology shift before Palo Alto's internal roadmap gets there. Refreshingly blunt for a CEO.

ALEX: There was also a fun exchange about the CyberArk integration — a new "Modern PAM" product just went GA, and Nikesh made the case that identity security for AI agents and machine identities is a wide-open category with no established leader yet, which is where he thinks Idira has a real head start.

JORDAN:

This episode includes AI-generated content.